MoneyWorks4Me

The sales is pegged at Rs. 119.80 millions for the September 2021 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 166.94 millions during the year-ago period.The Net Loss for the quarter ended September 2021 is Rs. -108.48 millions as compared to Net Loss of Rs. -63.90 millions of corresponding quarter ended September 2020 Operating profit Margin for the quarter ended September 2021 further decreased to -76.56% as compared to -30.28% of corresponding quarter ended September 2020


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 119.80 166.94 -28.24 187.35 282.63 -33.71 537.00 334.12 60.72
Other Income 1.32 0.71 85.92 1.62 1.21 33.88 6.21 3.65 70.14
PBIDT -76.56 -30.28 152.84 -141.52 -72.80 94.40 -169.56 -182.65 -7.17
Interest 17.76 21.25 -16.42 32.88 33.57 -2.06 62.79 59.28 5.92
PBDT -94.32 -51.53 83.04 -174.40 -106.37 63.96 -232.35 -241.93 -3.96
Depreciation 14.16 12.37 14.47 28.32 24.74 14.47 51.24 46.79 9.51
PBT -108.48 -63.90 69.77 -202.72 -131.11 54.62 -283.59 -288.72 -1.78
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -108.48 -63.90 69.77 -202.72 -131.11 54.62 -283.59 -288.72 -1.78
Equity 215.61 196.21 9.89 215.61 196.21 9.89 196.21 180.01 9.00
PBIDTM(%) -63.91 -18.14 252.33 -75.54 -25.76 193.26 -31.58 -54.67 -42.24

Krebs Biochem.&Inds Share Price

55.90 -2.10 (-3.62%)
14-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1924.90
Dr. Reddys Labs. 1202.00
Cipla 1450.00
Lupin 2235.00
Zydus Lifesciences 1140.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: